Clinical Trials Browser

Phase 2 × Not yet recruiting × Pemetrexed × Clear all

NCT07415031 2026-04-08

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Phase 2 Not yet recruiting

Other solid neoplasm

Solid Tumors

NCT07492680 2026-03-25

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Phase 2 Not yet recruiting

CNSDermatologicGastrointestinal

Brain Neoplasms, Melanoma, Pancreatic Neoplasms

NCT07486817 2026-03-23

Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

Phase 2 Not yet recruiting

Lung Neoplasms

NCT07420439 2026-02-19

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

Phase 2 Not yet recruiting

Lung Diseases, Interstitial

NCT07416058 2026-02-17

PHOENIX

Phase 2 Not yet recruiting

Diabetes Mellitus, Insulin-Dependent, 12, Adenocarcinoma of Lung

NCT07405190 2026-02-12

Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07234058 2026-02-11

LAG-MAPS

Phase 2 Not yet recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT07229339 2026-02-05

Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

Lung Non-Squamous Non-Small Cell Carcinoma

NCT07365410 2026-01-26

Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

Phase 2 Not yet recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT07309952 2025-12-30

SACTION 2501

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07274384 2025-12-10

HYPERBOLIC

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasms, Disease Progression

NCT07256509 2025-12-05

A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06944470 2025-04-25

JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC

Phase 2 Not yet recruiting

NSCLC

NCT06890182 2025-03-21

Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06861218 2025-03-06

Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases

Phase 2 Not yet recruiting

Meningeal Carcinomatosis

NCT06746870 2024-12-24

A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer

Phase 2 Not yet recruiting

NSCLC

NCT06688656 2024-11-14

Peri-E

Phase 2 Not yet recruiting

Lung Neoplasms

NCT06497543 2024-09-19

Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic

Phase 2 Not yet recruiting

Small Cell Lung Carcinoma

NCT06514027 2024-07-23

Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06475755 2024-06-26

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06045767 2024-06-03

T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer

Phase 2 Not yet recruiting

Non-small Cell Lung Cancer Metastatic

NCT06391008 2024-04-30

Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer

Phase 2 Not yet recruiting

Stereotactic Radiotherapy; Evoximab (AK112); New Adjuvant Therapy for Non-small Cell Lung Cancer

NCT06109402 2023-12-19

Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06142617 2023-11-21

A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05891080 2023-06-06

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05132985 2021-12-10

Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT04153734 2019-11-06

Evolution

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung